{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:22:50Z","timestamp":1793017370810,"version":"4.5.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> To comprehensively assess rebound effects by comparing myopia progression during atropine treatment and after discontinuation.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A systematic search of PubMed, EMBASE, Cochrane CENTRAL, and <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> was conducted up to 20 September 2023, using the keywords \u201cmyopia,\" \u201crebound,\u201d and \u201cdiscontinue.\" Language restrictions were not applied, and reference lists were scrutinized for relevant studies. Our study selection criteria focused on randomized control trials and interventional studies involving children with myopia, specifically those treated with atropine or combination therapies for a minimum of 6 months, followed by a cessation period of at least 1 month. The analysis centered on reporting annual rates of myopia progression, considering changes in spherical equivalent (SE) or axial length (AL). Data extraction was performed by three independent reviewers, and heterogeneity was assessed using I<jats:sup>2<\/jats:sup> statistics. A random-effects model was applied, and effect sizes were determined through weighted mean differences with 95% confidence intervals Our primary outcome was the evaluation of rebound effects on spherical equivalent or axial length. Subgroup analyses were conducted based on cessation and treatment durations, dosage levels, age, and baseline SE to provide a nuanced understanding of the data.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The analysis included 13 studies involving 2060 children. Rebound effects on SE were significantly higher at 6 months (WMD, 0.926 D\/y; 95%CI, 0.288\u20131.563 D\/y; <jats:italic>p<\/jats:italic> = .004) compared to 12 months (WMD, 0.268 D\/y; 95%CI, 0.077\u20130.460 D\/y; <jats:italic>p<\/jats:italic> = .006) after discontinuation of atropine. AL showed similar trends, with higher rebound effects at 6 months (WMD, 0.328\u00a0mm\/y; 95%CI, 0.165\u20130.492\u00a0mm\/y; <jats:italic>p<\/jats:italic> &amp;lt; .001) compared to 12 months (WMD, 0.121\u00a0mm\/y; 95%CI, 0.02\u20130.217\u00a0mm\/y; <jats:italic>p<\/jats:italic> = .014). Sensitivity analyses confirmed consistent results. Shorter treatment durations, younger age, and higher baseline SE levels were associated with more pronounced rebound effects. Transitioning or stepwise cessation still caused rebound effects but combining optical therapy with atropine seemed to prevent the rebound effects.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our meta-analysis highlights the temporal and dose-dependent rebound effects after discontinuing atropine. Individuals with shorter treatment durations, younger age, and higher baseline SE tend to experience more significant rebound effects. Further research on the rebound effect is warranted.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold> [<jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=463093<\/jats:ext-link>], identifier [registration number]<\/jats:p>","DOI":"10.3389\/fphar.2024.1343698","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T04:38:27Z","timestamp":1705898307000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Myopia progression after cessation of atropine in children: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Ssu-Hsien","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Chiao","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chieh","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Hung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Jen","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41572-020-00231-4","volume":"6","author":"Baird","year":"2020","journal-title":"Myopia. Nat. Rev. Dis. Prim."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1167\/iovs.13-11813","article-title":"A prospective study of spherical refractive error and ocular components among Northern Irish schoolchildren (the NICER study)","volume":"54","author":"Breslin","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ophtha.2021.04.032","article-title":"The risks and benefits of myopia control","volume":"128","author":"Bullimore","year":"2021","journal-title":"Ophthalmol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"107778","DOI":"10.1016\/j.exer.2019.107778","article-title":"An overview of myopia genetics","volume":"188","author":"Cai","year":"2019","journal-title":"Exp. Eye Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-981-13-8491-2_3","article-title":"The economic and societal impact of myopia and high myopia","author":"Chua","year":"2020","journal-title":"Updat. Myopia A Clin. Perspective"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.4103\/ijo.IJO_3354_20","article-title":"Compliance in usage of low-dose atropine for prevention of progression of myopia in Indian children","volume":"69","author":"Dalal","year":"2021","journal-title":"Indian J. Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/519276a","article-title":"The myopia boom","volume":"519","author":"Dolgin","year":"2015","journal-title":"Nat."},{"key":"B10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/vision6040073","article-title":"Low-concentration atropine monotherapy vs. Combined with MiSight 1 Day contact lenses for myopia management","volume":"6","author":"Erdinest","year":"","journal-title":"Vis. (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4103\/tjo.tjo_31_22","article-title":"Myopia control utilizing low-dose atropine as an isolated therapy or in combination with other optical measures: a retrospective cohort study","volume":"13","author":"Erdinest","year":"2023","journal-title":"Taiwan J. Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101475","DOI":"10.1016\/j.clae.2021.101475","article-title":"Decreased effectiveness of 0.01% atropine treatment for myopia control during prolonged COVID-19 lockdowns","volume":"45","author":"Erdinest","year":"","journal-title":"Cont. Lens Anterior Eye"},{"key":"B13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis","volume":"135","author":"Gong","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","article-title":"Efficacy and safety of 8 atropine concentrations for myopia control in children: a network meta-analysis","volume":"129","author":"Ha","year":"2022","journal-title":"Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10384-023-01012-8","article-title":"Assessment of myopic rebound effect after discontinuation of treatment with 0.01% atropine eye drops in Japanese school-age children","volume":"67","author":"Hieda","year":"2023","journal-title":"Jpn. J. Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1001\/jamaophthalmol.2020.3451","article-title":"Association of age at myopia onset with risk of high myopia in adulthood in a 12-year follow-up of a Chinese cohort","volume":"138","author":"Hu","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","article-title":"Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis","volume":"123","author":"Huang","year":"2016","journal-title":"Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.64.12.6","article-title":"Longitudinal changes in axial length and spherical equivalent in children and adolescents with high myopia","volume":"64","author":"Jiang","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.62.5.6","article-title":"IMI prevention of myopia and its progression","volume":"62","author":"Jonas","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/OPX.0000000000001884","article-title":"Effect of combining 0.01% atropine with soft multifocal contact lenses on myopia progression in children","volume":"99","author":"Jones","year":"2022","journal-title":"Optom. Vis. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/cxo.12666","article-title":"Optical and pharmacological strategies of myopia control","volume":"101","author":"Kang","year":"2018","journal-title":"Clin. Exp. Optom."},{"key":"B23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/OPX.0000000000000178","article-title":"Millodot M. Atropine slows myopia progression more in Asian than white children by meta-analysis","volume":"91","author":"Li","year":"2014","journal-title":"Optom. Vis. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1097\/OPX.0000000000000097","article-title":"Treatment outcomes of myopic anisometropia with 1% atropine: a pilot study","volume":"90","author":"Lin","year":"2013","journal-title":"Optom. Vis. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.ophtha.2010.01.020","article-title":"Prevalence and progression of myopic retinopathy in Chinese adults: the Beijing Eye Study","volume":"117","author":"Liu","year":"2010","journal-title":"Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.ophtha.2011.03.012","article-title":"Myopia as a risk factor for open-angle glaucoma: a systematic review and meta-analysis","volume":"118","author":"Marcus","year":"2011","journal-title":"Ophthalmology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/ijpvm.ijpvm_175_22","article-title":"The preventive role of atropine eye drops on myopia progression: a double-blind randomized clinical trial","volume":"14","author":"Medghalchi","year":"2023","journal-title":"Int. J. Prev. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2017.09.004","article-title":"The epidemics of myopia: aetiology and prevention","volume":"62","author":"Morgan","year":"2018","journal-title":"Prog. Retin Eye Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","article-title":"Myopia","volume":"379","author":"Morgan","year":"2012","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"29","author":"Page","year":"2021","journal-title":"Bmj."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ajo.2013.06.005","article-title":"Myopia and age-related cataract: a systematic review and meta-analysis","volume":"156","author":"Pan","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/eye.2016.78","article-title":"Effectiveness study of atropine for progressive myopia in Europeans","volume":"30","author":"Polling","year":"2016","journal-title":"Eye (Lond)."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","article-title":"A 3-year follow-up study of atropine treatment for progressive myopia in Europeans","volume":"34","author":"Polling","year":"2020","journal-title":"Eye (Lond)."},{"key":"B34","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/APO.0000000000000224","article-title":"Myopia genetics-the asia-pacific perspective","volume":"5","author":"Rong","year":"2016","journal-title":"Asia Pac J. Ophthalmol. (Phila)."},{"key":"B36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1167\/iovs.64.6.7","article-title":"IMI 2023 digest","volume":"64","author":"Sankaridurg","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"key":"B38","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B39","doi-asserted-by":"publisher","first-page":"101723","DOI":"10.1016\/j.clae.2022.101723","article-title":"Combined 0.01% atropine with orthokeratology in childhood myopia control (AOK) study: a 2-year randomized clinical trial","volume":"46","author":"Tan","year":"2023","journal-title":"Cont. Lens Anterior Eye."},{"key":"B40","doi-asserted-by":"publisher","first-page":"M89","DOI":"10.1167\/iovs.18-25965","article-title":"IMI - myopia genetics report","volume":"60","author":"Tedja","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaophthalmol.2016.4009","article-title":"Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia","volume":"134","author":"Tideman","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","article-title":"Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine","volume":"116","author":"Tong","year":"2009","journal-title":"Ophthalmol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1136\/bjophthalmol-2020-318256","article-title":"Progression of myopia in children and teenagers: a nationwide longitudinal study","volume":"106","author":"Tricard","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","article-title":"Biological mechanisms of atropine control of myopia","volume":"46","author":"Upadhyay","year":"2020","journal-title":"Eye Contact Lens"},{"key":"B45","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1001\/jamaophthalmol.2023.3076","article-title":"Atropine, 0.01%, for myopia control","volume":"141","author":"Walline","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/jcm7090259","article-title":"The synergistic effects of orthokeratology and atropine in slowing the progression of myopia","volume":"7","author":"Wan","year":"2018","journal-title":"J. Clin. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"323468","DOI":"10.1136\/bjo-2023-323468","article-title":"Normative value of hyperopia reserve and myopic shift in Chinese children and adolescents aged 3-16 years","author":"Wang","year":"2023","journal-title":"Br. J. Ophthalmol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1111\/aos.15235","article-title":"Myopia progression after cessation of low-dose atropine eyedrops treatment: a two-year randomized, double-masked, placebo-controlled, cross-over trial","volume":"101","author":"Wei","year":"2023","journal-title":"Acta Ophthalmol. Mar."},{"key":"B49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ophtha.2012.07.048","article-title":"Subfoveal choroidal thickness: the Beijing eye study","volume":"120","author":"Wei","year":"2013","journal-title":"Ophthalmol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1167\/iovs.18-24032","article-title":"Prevalence, risk factors, and impact of myopic macular degeneration on visual impairment and functioning among adults in Singapore","volume":"59","author":"Wong","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)."},{"key":"B52","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/APO.0000000000000236","article-title":"Epidemiology of myopia","volume":"5","author":"Wu","year":"2016","journal-title":"Asia Pac J. Ophthalmol. (Phila)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ajo.2020.01.003","article-title":"Changes in choroidal thickness varied by age and refraction in children and adolescents: a 1-year longitudinal study","volume":"213","author":"Xiong","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/iovs.64.4.13","article-title":"Potential choroidal mechanisms underlying atropine's antimyopic and rebound effects: a mediation analysis in a randomized clinical trial","volume":"64","author":"Xu","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2021.12.014","article-title":"The association of choroidal thickening by atropine with treatment effects for myopia: two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study","volume":"237","author":"Yam","year":"","journal-title":"Am. J. Ophthalmol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report","volume":"129","author":"Yam","year":"","journal-title":"Ophthalmol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/iovs.61.14.15","article-title":"Effects of atropine treatment on choroidal thickness in myopic children","volume":"61","author":"Ye","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s40123-022-00572-1","article-title":"Efficacy and safety of consecutive use of 1% and 0.01% atropine for myopia control in Chinese children: the atropine for children and adolescent myopia progression study","volume":"11","author":"Ye","year":"2022","journal-title":"Ophthalmol. Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1074272","DOI":"10.3389\/fpubh.2023.1074272","article-title":"Effect of atropine 0.01% on myopia control in children aged 6-13 years during the 2022 lockdown in Shanghai","volume":"11","author":"Yu","year":"2023","journal-title":"Front. Public Health"},{"key":"B60","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 Years: a randomized clinical trial","volume":"141","author":"Zadnik","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"176","DOI":"10.7150\/ijms.39365","article-title":"Efficacy and safety of 1% atropine on retardation of moderate myopia progression in Chinese school children","volume":"17","author":"Zhu","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s00417-018-4078-6","article-title":"Current trends among pediatric ophthalmologists to decrease myopia progression-an international perspective","volume":"256","author":"Zloto","year":"2018","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1343698\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T04:38:30Z","timestamp":1705898310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1343698\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":62,"alternative-id":["10.3389\/fphar.2024.1343698"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1343698","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"article-number":"1343698"}}